首页 | 本学科首页   官方微博 | 高级检索  
     


Thallium-201 as a myocardial imaging agent
Authors:H. William Strauss  Bertram Pitt  
Affiliation:1. Massachusetts General Hospital, Boston, Mass., USA;2. Johns Hopkins Medical Institution, Md., USA
Abstract:The field of myocardial perfusion imaging has made many advances but still is in its infancy. The limitations in the technology at this time include limited instrument resolution of 6-9 mm, intrinsic at the energy of the mercury x-ray; significant Rayleigh scatter, which is particularly distrubing because this scatter cannot be removed by pulse-height analysis; and an effective half-life of thallium in the myocardium, which makes repeated imaging over a short period of time very difficult. Although hopes for the development of a technetium-labeled myocardial imaging tracer have burnt brightly, no new agents are presently in sight. Resolution with a technetium-labeled tracer would almost double that of thallium, and the dose that could be administered to the patient would increase by at least a factor of 4. The effective half-life of the tracer in the myocardium would permit multiple images to be obtained at least in the same day. Even with the limitations of the current techniques, however, myocardial perfusion imaging can make a real contribution to the care of the patients with heart disease. Thallium is now produced commercially and reasonably easily obtained. Extraction of thallium by the myocardium is probably somewhat, but not exactly, analogous to potassium. The tracer has major applications in defining shape and size of the heart, thickness of muscle, and especially myocardial ischemia and infarction. This review is aimed at providing a current perspective of these uses.
Keywords:Reprint requests should be addressed to H. William Strauss   M.D.   Nuclear Medicine Division   Massachusetts General Hospital   Boston   Mass. 02114.
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号